Vimarsana
Biggest News Aggregation in the World

Page 3 - Dose Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dose Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dose Management Today - Breaking & Trending Today

'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan - Vimarsana News

'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan

Published: September 25, 2023

/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that "LEQEMBI® Intravenous Infusion" (200 mg, 500mg, lecanemab)...

Source: prnewswire.com
Related Topics:
Uppsala LanUnited KingdomSouth KoreaGreat BritainOskar BossonGunilla OsswaldJiang MillingtonUppsala UniversityNational Institute OnNational Institutes Of HealthDrug AdministrationWashington University School Of MedicineVp CommunicationsAlzheimer Clinical Trial ConsortiumAd Cooperative StudyJapanese Ministry Of HealthAlzheimer Network Trials UnitNasdaq StockholmClinical Dementia Rating SumDaily Living ScaleMild Cognitive ImpairmentClinical TrialsNew England JournalJapanese MinistryBiogen Japan
'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan (2) - Vimarsana News

'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan (2)

Published: September 25, 2023

STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

Source: europapress.es
Related Topics:
South KoreaUnited KingdomUppsala LanGreat BritainOskar BossonJiang MillingtonGunilla OsswaldWashington University School Of MedicineAlzheimer Network Trials UnitAlzheimer Clinical Trial ConsortiumJapanese Ministry Of HealthNational Institute OnDrug AdministrationUppsala UniversityVp CommunicationsAd Cooperative StudyNational Institutes Of HealthNasdaq StockholmClinical Dementia Rating SumDaily Living ScaleMild Cognitive ImpairmentClinical TrialsNew England JournalJapanese MinistryBiogen Japan
'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan (1) - Vimarsana News

'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan (1)

Published: September 25, 2023

STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

Source: europapress.es
Related Topics:
South KoreaUppsala LanUnited KingdomGreat BritainGunilla OsswaldOskar BossonJiang MillingtonVp CommunicationsUppsala UniversityDrug AdministrationJapanese Ministry Of HealthNational Institute OnAlzheimer Clinical Trial ConsortiumAlzheimer Network Trials UnitWashington University School Of MedicineNational Institutes Of HealthAd Cooperative StudyNasdaq StockholmClinical Dementia Rating SumDaily Living ScaleMild Cognitive ImpairmentClinical TrialsNew England JournalJapanese MinistryBiogen Japan
'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan (3) - Vimarsana News

'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan (3)

Published: September 25, 2023

STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

Source: europapress.es
Related Topics:
Uppsala LanUnited KingdomSouth KoreaGreat BritainGunilla OsswaldOskar BossonJiang MillingtonNational Institutes Of HealthAd Cooperative StudyDrug AdministrationUppsala UniversityVp CommunicationsJapanese Ministry Of HealthNational Institute OnAlzheimer Clinical Trial ConsortiumAlzheimer Network Trials UnitWashington University School Of MedicineNasdaq StockholmClinical Dementia Rating SumDaily Living ScaleMild Cognitive ImpairmentClinical TrialsNew England JournalJapanese MinistryBiogen Japan
Latest analysis of lecanemab's effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 202 - Vimarsana News

Latest analysis of lecanemab's effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 202

Published: July 20, 2023

STOCKHOLM, July 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

Source: europapress.es
Related Topics:
United StatesSouth KoreaUppsala LanUnited KingdomGreat BritainOskar BossonBiomarker ModificationinAlzheimer Network Trials UnitUppsala UniversityNational Institutes Of HealthAlzheimer Association International ConferenceNational Institute OnAlzheimer Clinical Trial ConsortiumWashington University School Of MedicineDrug AdministrationVp CommunicationsNasdaq StockholmAssociation International ConferenceClinical Dementia Rating SumClinical TrialsNew England JournalAmyloid ReductionDownstream Biomarker ModificationinAchieve Comparable EfficacyImproved Safety Compared